Paulash Mohsen Biography and Net Worth

Insider of Yumanity Therapeutics

Mr. Paulash Mohsen is a Chief Business Officer at Yumanity Therapeutics, Inc. and a Chief Business Officer at Yumanity, Inc. Mr. Mohsen was previously employed as a Vice President-Strategy by Pfizer Inc., a Country Manager-Canada Region by Cubist Pharmaceuticals LLC, and a Vice President-Strategy & Business Operations by Optimer Pharmaceuticals LLC. He received his undergraduate degree from Brown University, a graduate degree from Massachusetts Institute of Technology and an MBA from Harvard Business School.

How do I contact Paulash Mohsen?: The corporate mailing address for Mr. Mohsen and other Yumanity Therapeutics executives is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. Yumanity Therapeutics can also be reached via phone at (617) 409-5300 and via email at [email protected]. Learn More on Paulash Mohsen's contact information.
Has Paulash Mohsen been buying or selling shares of Yumanity Therapeutics?: Paulash Mohsen has not been actively trading shares of Yumanity Therapeutics during the last ninety days. Most recently, Paulash Mohsen sold 1,958 shares of the business's stock in a transaction on Thursday, February 3rd. The shares were sold at an average price of $1.83, for a transaction totalling $3,583.14. Learn More on Paulash Mohsen's trading history.

Paulash Mohsen Insider Trading History at Yumanity Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2022	Sell	1,958	$1.83	$3,583.14

Paulash Mohsen Buying and Selling Activity at Yumanity Therapeutics

Yumanity Therapeutics Company Overview

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $0.68

$0.56

$1.89

2 Week Range

Now: N/A

Volume

6,790 shs

Average Volume

473,083 shs

Market Capitalization

$7.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.